Research has revealed a notable decrease in AIM2 expression within GC tumor tissues, with AIM2 deficiency correlating with factors such as tumor size, lymph node metastasis (LNM), tumor, lymph node metastasis (TNM) stage, and unfavorable prognostic outcomes in GC patients. This evidence concerns the gene AIM2 and gastric cancer.